A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with
acute myeloid leukemia (AML) with certain genetic alterations.
This protocol has 3 separate arms that will investigate the benefits and risks of adding
ziftomenib to standard-of...
Age: 18 years - 66+
Gender: All
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
This study collects blood and tissue samples for research of human immunodeficiency virus
(HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and
tissue samples and studying biomarkers in the laboratory may help doctors to learn how
are ...
Age: 18 years - 66+
Gender: All
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for
the first time. The trial includes a Main Study and four sub-studies. In the Main Study
(including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in
patie...
Age: 18 years - 66+
Gender: All
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
This trial will evaluate magrolimab, a monoclonal antibody which is designed to block a
protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with
magrolimab may enable the body's immune system to find and destroy the cancer cells. In thi...
Age: 18 years - 66+
Gender: All
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
Age: Birth - 66+
Gender: All
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood
units (CBUs) in pediatric and adult patients with hematologic malignancies and other
indications.
Age: Birth - 66+
Gender: All